Testing anselamimab for localized amyloid tumors
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This early-stage trial tests a new drug called anselamimab for AL amyloidoma—a rare condition where abnormal protein deposits form tumors in one part of your body. The study aims to see if this drug can help shrink or control these deposits in patients who have a visible, removable tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- AL amyloid confirmed by biopsy (tissue sample under a microscope)
- Amyloid deposits visible on imaging (ultrasound or CT scan)
- Age 18 or older and able to tolerate treatment (ECOG score 0–3)
- Healthy bone marrow, liver, and kidney function (confirmed by blood tests)
- Amyloid only in one organ, with no involvement of the heart, kidneys, or liver
- Willing to use contraception and not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.